BIOCHEMICAL ALTERATIONS IN ONCOPEDIATRIC PATIENTS DURING SEPSIS

Full Text

Introduction. Sepsis remains one of the most pressing problems in modern medicine due to the growth of its prevalence and consistently high mortality. Childhood cancer patients receiving immunosuppressive therapy represent a particular risk group for the development of sepsis. In recent years, a new marker, presepsin, has been proposed for the early diagnosis of sepsis, which is a soluble fragment of the CD14 receptor. Material and methods. The study enrolled 112 patients with cancer up to 18 years old who were diagnosed with sepsis based on clinical symptoms. The patients were divided into 3 groups: survivors (n = 85), non-survivors (n = 17), control (n = 13). The analysis included indicators: the level of presepsin and general blood biochemical parameters. Presepsin was determined on a Pathfast immuno-chemiluminescent analyzer, biochemical parameters were measured on a Pentra 400 analyzer. Results and discussion. Comparison of medians showed significant differences in the groups of survivors and non-survivors in terms of presepsin (69.8 vs 1438 pg/ml, p < 0.0001). Comparison with reference values showed that the level of presepsin in the group of the dead was increased 13 times compared with the normal values, 4.7 times compared with the group of survivors and 24 times compared with the control group. The median of total bilirubin in the group of non-survivors was increased by 3.65 times, and the direct one - by 13.8 times compared with normal values. In the group of survivors, the median does not exceed reference range. In the group of survivors, significant correlations of presepsin with total bilirubin and GGT were found (r = 0.34 and r = 0.4, p < 0.01). In the group of non-survivors, the identified correlations between presepsin and total and direct bilirubin, iron and urea (r = 0.77, r = 0.79, r = 0.59, r = 0.64, p < 0.01) confirm the assumption increased erythrocyte breakdown in sepsis and aggravation of multiple organ failure.

About the authors

E G Golovnya

N.N. Blokhin National Medical Research Center of Oncology

A V Lebedeva

N.N. Blokhin National Medical Research Center of Oncology

T Yu Kharitidi

N.N. Blokhin National Medical Research Center of Oncology

A V Sotnikov

N.N. Blokhin National Medical Research Center of Oncology

References

Supplementary files